WCN26-3349 THE FIRST IRAQI EXPERIENCE OF MANAGING AtTYPICAL UREMIC SYNDROME (aHUS): FROM GENETIC DIAGNOSIS TO THE USE OF ANTI-C5 THERAPY, THE IRAQI aHUS TASKFORCE

Read full text Summarise with VIRAT
Authors: Ala Ali, Onss Ali Saheb Al-Omairi
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Atypical hemolytic uremic syndrome (aHUS) is a rare disorder caused by abnormal activation of the alternative complement pathway. If not diagnosed and treated promptly, it can lead to significant morbidity and mortality due to various renal and extrarenal complications, as well as the long-term effects of CKD and ESKD. Anti-C5 therapies have transformed and changed the natural course of aHUS, turning it from a deadly disease into a more manageable condition.

Fields of Study & Subjects

Complement system in diseases Renal Diseases and Glomerulopathies Coagulation Bradykinin Polyphosphates and Angioedema

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105100–105100
Publication date
25 March 2026
Language
EN